Association of Baseline Inflammation With Effectiveness of Nutritional Support Among Patients With Disease-Related Malnutrition
Authors: Meret Merker, Martina Felder, Louise Gueissaz, Rebekka Bolliger, Pascal Tribolet, Nina Kägi-Braun, Filomena Gomes, Claus Hoess, Vojtech Pavlicek, Stefan Bilz, Sarah Sigrist, Michael Brändle, Christoph Henzen, Robert Thomann, Jonas Rutishauser, Drahomir Aujesky, Nicolas Rodondi, Jaques Donzé, Zeno Stanga, Beat Mueller, Philipp Schuetz
Journal: JAMA Network Open (2020)

<h3>Importance</h3> Inflammation is a key driver of malnutrition during illness and is often accompanied by metabolic effects, including insulin resistance and reduction of appetite. However, it still remains unclear if inflammation influences the response to nutritional support among patients with disease-related malnutrition. <h3>Objective</h3> To examine whether patients' baseline inflammatory status is associated with the effect of nutritional support on 30-day mortality. <h3>Design, Setting, and Participants</h3> This is a secondary analysis of the Effect of Early Nutritional Support on Frailty, Functional Outcomes, and Recovery of Malnourished Medical Inpatients Trial (EFFORT), a randomized clinical trial conducted in 8 Swiss hospitals from April 2014 to February 2018. A total of 1950 participants who had C-reactive protein measurements at the time of admission were included in this secondary analysis. Data analysis was conducted between June and July 2019. <h3>Interventions</h3> Hospitalized patients at risk for malnutrition were randomly assigned to receive protocol-guided individualized nutritional support to reach protein and energy goals (intervention group) or standard hospital food (control group). <h3>Main Outcomes and Measures</h3> The primary end point was 30-day mortality. Based on C-reactive protein levels at admission, patients were stratified into groups with low, moderate, or high inflammation (&lt;10 mg/L, 10-100 mg/L, and &gt;100 mg/L, respectively). <h3>Results</h3> A total of 1950 patients (median [interquartile range] age, 75 [65-83] years; 1025 [52.6%] men) were included; 533 (27.3%) had low levels of inflammation, 894 (45.9%) had moderate levels of inflammation, and 523 (26.8%) had high levels of inflammation. Compared with the control group, patients receiving nutritional support showed a significant reduction in 30-day mortality, regardless of C-reactive protein level (adjusted odds ratio, 0.61; 95% CI, 0.43-0.86;<i>P</i> = .005). In the subgroup of patients with high inflammation, there was no beneficial effect of nutritional support (adjusted odds ratio, 1.32; 95% CI, 0.70-2.50;<i>P</i> = .39), providing evidence that inflammation has a significant modifying association (<i>P</i>for interaction = .005). <h3>Conclusions and Relevance</h3> Based on this secondary analysis of a multicenter randomized trial, a patient's admission inflammatory status was associated with their response to nutritional support. If validated in future clinical trials, nutritional support may need to be individualized based on a patient's initial presentation and markers of inflammation. These results may also help to explain some of the heterogeneity in treatment effects of nutrition seen in previous critical care trials. <h3>Trial Registration</h3> ClinicalTrials.gov Identifier:NCT02517476